Jakob Haldor Topsoe - Aug 14, 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Director, 10%+ Owner
Signature
/s/ Jakob Haldor Topsoe
Stock symbol
IGMS
Transactions as of
Aug 14, 2025
Transactions value $
$0
Form type
4
Date filed
8/14/2025, 05:27 PM
Previous filing
Jul 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Topsoe Jakob Haldor Director, 10%+ Owner C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW /s/ Jakob Haldor Topsoe 2025-08-14 0001785882

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Disposed to Issuer -91.7K -100% 0 Aug 14, 2025 Direct F1
transaction IGMS Common Stock Disposed to Issuer -10.4M -100% 0 Aug 14, 2025 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Non-Voting Common Stock Disposed to Issuer $0 -5.04M -100% $0.00 0 Aug 14, 2025 Common Stock 5.04M See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jakob Haldor Topsoe is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock and Non-Voting Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.
F2 Prior to the Merger, the shares were held directly by Topsoe Holding A/S. Jakob Haldor Topsoe, Christina Teng Topsoe, Anne Haugwitz-Hardenberg-Reventlow, Emil Oigaard, Thomas Schleicher and Birgitte Nielsen, members of the board of directors of Topsoe Holding A/S, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any.
F3 Prior to the Merger, the shares of Non-Voting Common Stock were convertible into the Issuer's Common Stock on a 1-for-1 basis (subject to a 4.99% beneficial ownership limitation that may be increased or decreased by the holder of such shares) and had no expiration date.